tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

PYC Therapeutics Announces Board Changes Amidst RNA Therapy Advancements

Story Highlights
PYC Therapeutics Announces Board Changes Amidst RNA Therapy Advancements

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

PYC Therapeutics Limited ( (AU:PYC) ) just unveiled an update.

PYC Therapeutics Limited has announced changes in its board of directors, with new appointments and final interest notices for several directors. These changes are part of the company’s ongoing efforts to strengthen its leadership team as it continues to advance its RNA therapeutic programs, which could impact its market positioning and stakeholder interests.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company focused on developing RNA therapies for genetic diseases. The company uses a proprietary drug delivery platform to enhance the effectiveness of precision medicines, targeting monogenic diseases with high clinical development success rates.

Average Trading Volume: 886,850

Technical Sentiment Signal: Sell

Current Market Cap: A$522M

Learn more about PYC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1